4-丁氧基-3-甲基苯甲醛 | 820236-97-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-丁氧基-3-甲基苯甲醛
• 英文名称: 4-butoxy-3-methylbenzaldehyde
• CAS: 820236-97-3
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.258
• InChiKey: OSWMOBLBJZTDBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-甲基-4-羟基苯甲醛 、 正溴丁烷 生成 4-丁氧基-3-甲基苯甲醛
  参考文献：
  名称：

  Pyrazolidinedione derivatives

  摘要：

  本发明涉及烷基亚胺吡唑啉二酮衍生物化合物，其为有效的血小板ADP受体拮抗剂，可预防血小板聚集和血栓形成。因此，本发明还涉及包含该化合物的制药组合物，以及用于预防或治疗与血小板聚集有关的外周、内脏、肝、肾、心血管和脑血管疾病和病状的方法，包括血栓形成，在人类和其他哺乳动物中。本发明还提供一种制造烷基亚胺吡唑啉二酮衍生物的方法。

  公开号：

  US20070037846A1

文献信息

• [EN] PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS<br/>[FR] DERIVES DE PYRAZOLIDINEDIONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'AGREGATION DES PLAQUETTES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005002574A1

  公开（公告）日：2005-01-13

  Pyrazolidinedione derivatives of the general formula (I), wherein R1 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and R2 is aryl or heteroaryl; tautomers thereof; geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof; pharmaceutically acceptable acid addition salts of compounds which are basic; pharmaceutically acceptable salts of compounds containing acidic groups with bases; pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups; prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; are active as platelet adenosine diphosphate receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepaticand renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, particularly thrombosis, and, respectively, for the manufacture of corresponding medicaments. Some, albeit not all, of the compounds of the above formula (I) are novel.

  一般公式（I）的吡唑烷二酮衍生物，其中R1是氢，可选地取代烷基，环烷基，芳基，芳烷基，杂芳基或杂芳烷基；R2是芳基或杂芳基；其互变异构体；其几何异构体及这些几何异构体的互变异构体，包括公式（I）的单个化合物的混合物，或其互变异构体，及其几何异构体，或其互变异构体；药物可接受的酸加成盐基本化合物；含有酸性基团的化合物与碱的药物可接受盐；含有羟基或羧基的化合物的药物可接受酯；以及存在前药形成基团的化合物的前药；以及它们的 hydrates 或 solvates；作为血小板二磷酸腺苷受体拮抗剂活性，可用于预防或治疗外周血管疾病，内脏、肝脏和肾脏血管疾病，心血管疾病和脑血管疾病或与血小板聚集相关的病症，尤其是血栓症，并且分别用于制造相应的药物。上述公式（I）中的一些化合物是新颖的，但并非全部。
• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20070276138A1

  公开（公告）日：2007-11-29

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W. R 1 is —(CH 2 ) n —CH(OR 2 )—(CH 2 ) m E, —(CH)═C(OR 2 )—(CH 2 ) m E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or —(CH)═C(Y)—(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 -alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C 0-4 -alkyl; R 2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or —C(S)NR 5 R 6 . R 3 is —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is —O—, —CH 2 —, —CH 2 CH 2 — or —CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  公开了一种化合物，其结构式表示为（I）：其中Ar是取代或未取代的芳香族基团。Q是共价键，-CH2-或-CH2CH2-；W是取代或未取代的烷基或取代或未取代的异烷基连接基团，长度为两到十个原子，优选长度为两到七个原子。苯环A可以选择性地用最多四个取代基取代R1和W。R1是-(CH2)n-CH(OR2)-(CH2)mE，-(CH)=C(OR2)-(CH2)mE，-(CH2)n-CH(Y)-(CH2)mE或-(CH)=C(Y)-(CH2)mE；其中E是COOR3，C1-C3-烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，其中磺酰胺，酰基磺酰胺和四唑可以选择性地用一个或多个取代基取代，独立地选自C1-C6烷基，卤代烷基和芳基-C0-4-烷基；R2是-H，一种脂肪基，一种取代的脂肪基，卤代烷基，一种芳香基，一种取代的芳香基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或-C（S）NR5R6；R3是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；Y是-O-，-CH2-，-CH2CH2-或-CH═CH-，并与苯环A中与R1正交的碳原子键合；R4-R6独立地是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；n和m独立地为0、1或2。
• PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1638540A2

  公开（公告）日：2006-03-29
• US4024274A
  申请人：——

  公开号：US4024274A

  公开（公告）日：1977-05-17
• US7192982B2
  申请人：——

  公开号：US7192982B2

  公开（公告）日：2007-03-20